Background. The phosphatidylinositol 3-kinase p85 alpha regulatory subunit 1 gene (PIK3R1) encodes the PIK3R1 protein, which plays a direct role in insulin signaling. PIK3R1 (p85 regulatory subunit) connects firmly with the p110 catalytic subunit, and together these proteins form the phosphatidylinositol 3-kinase (PI3K) protein. PI3K is a key protein in the Akt signaling pathway, which regulates cell survival, growth, differentiation, glucose trafficking, and utilization. Defects in the insulin signaling cascade play an important role in the development of insulin resistance, which shares a common genetic basis for metabolic diseases such as type 2 diabetes (T2D), obesity and cardiovascular diseases.
Introduction
Insulin is a major hormone that regulates processes such as cellular growth, differentiation and apoptosis, in addition to glucose metabolism. Insulin acts on target tissues, mainly liver, muscle and adipose tissues, by binding to its receptor on the cell surface, leading to the autoactivation of tyrosine residues. Once activated, receptor phosphorylates the downstream signaling proteins known as the insulin receptor substrate (IRS) family, which has Src Homology 2 (SH2) domain-containing proteins. Then, phosphorylated IRS proteins activate other SH2 domaincontaining proteins, including the regulatory subunits of phosphatidylinositol 3-kinase (PI3K). PI3K catalyzes the conversion of phosphatidylinositol phosphate (PIP) 2 to PIP3, which activate Akt signaling, which itself regulates cell survival, growth, differentiation, glucose transporter type 4 (GLUT-4) trafficking, and glucose utilization. 1 Impaired activation of the insulin signaling pathway results in the decreased responsiveness of target tissues to normal circulating levels of insulin, a condition known as insulin resistance. Insulin resistance is a common pathogenesis in several metabolic diseases, such as type 2 diabetes (T2D), obesity and cardiovascular diseases.
Insulin resistance generally occurs as a result of postreceptor defects. 2 Especially, it is suggested that reductions in both IRS-l phosphorylation and insulin-stimulated PI3K activation leads to impaired insulin signal transduction. Additionally, other signaling molecules in this transduction, insulin signaling inhibitors such as ENPP1, PTP1B, and INPPL1, lipid accumulation in target tissues, and abnormal lipid metabolism can also contribute to insulin resistance. 3, 4 The PI3K enzyme is composed of 2 subunits, the p110 catalytic subunit and regulatory p85α subunit. 5 The p85α subunit stabilizes the p110 catalytic subunit and determines the level of activity. 5 Polymorphisms in the PIK3R1 gene, which encodes the p85 regulatory subunit of the PI3K enzyme, are associated with the development of diseases such as insulin resistance, obesity, T2D, and cancer. [6] [7] [8] In this study, we investigated the effects of single nucleotide polymorphisms (SNPs) rs3756668A→G (located in the 3'UTR region), rs706713C→T and rs3730089A→G (located in exons 1 and 6, respectively), rs7713645A→C and rs7709243C→T (both located in intron 1), and rs1550805C→T (located in intron 6) of the PIK3R1 gene on T2D.
Material and methods

Clinical samples
This study enrolled a total of 840 individuals, including 427 diabetic individuals (206 obese and 221 non-obese) and 413 nondiabetic individuals (138 obese and 275 non-obese). These individuals were selected from patients admitted to the Selçuk University Hospital, Department of Endocrinology (Konya, Turkey). The individuals in the diabetic group, who were diagnosed according to the guidelines of the American Diabetes Association (ADA), were over 30 years old and did not use insulin. Other types of diabetes (type 1 diabetes, maturity onset diabetes of the young -MODY, latent autoimmune diabetes of adults -LADA, drug-related and other types) were excluded. Obesity criteria was considered as body mass index (BMI) ≥30. The control group in this study included age-and BMI-matched nondiabetic individuals with no family history of diabetes. Written informed consent was obtained from each individual before participation in the study. The study was approved by the Ethics Committee of the Selçuk University Medical Faculty (Konya, Turkey). An oral glucose tolerance test (OGTT) was performed on the individuals considered as pre-diabetic. Individuals with impaired glucose tolerance or insulin resistance were excluded from the study.
Clinical analyses
Fasting plasma glucose, fasting insulin, HbA1C, c-peptide, cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), and triglyceride values were measured for both diabetic and control groups. Insulin resistance was determined using the homeostasis model assessment of insulin resistance (HOMA-IR) and was calculated as fasting plasma glucose (mmol/L) multiplied by fasting serum insulin (pmol/L) and divided by 22.5. An individual with a HOMA-IR value higher than 2.5 was considered resistant to insulin.
Genotyping
Genomic DNA was isolated from peripheral blood leukocytes using a standard proteinase K and sodium dodecyl sulphate (SDS) procedure. Target SNPs were analyzed using the real-time polymerase chain reaction (RT-PCR) technique and a TIB MolBiol LightSNiP kit (Roche, Basel, Switzerland). Six SNPs in the PIK3R1 gene were previously reported to be associated with the disease in the literature. Information about these target SNPs is shown in Table 1 .
Statistical analysis
Descriptive statistics were obtained for clinical and biochemical characteristics. Normally distributed parameters were compared using one-way analysis of variance (ANOVA), while parameters that did not show normal distributions were compared by Kruskal-Wallis test after transformation.
The differences between the patient and control groups in terms of genotype distribution or allele frequency were analyzed using Pearson's c 2 test. A c 2 goodness of fit test was used to evaluate Hardy-Weinberg equilibrium (HWE) in the patient and control groups. Analyses were performed using dominant, additive and recessive models. Dominance was defined in terms of allele 2 effects. In dominant allele 2 models, homozygous individuals for allele 1 were compared with carriers of allele 2. In recessive allele 2 models, homozygous individuals for allele 2 were compared with carriers of allele 1. Association between genotypes and T2D was tested by conducting a case-control study. Allele frequencies of SNPs in the patient and control groups were evaluated using odds ratio (OR). We performed logistic regression analysis by considering not only dominant, additive and recessive models of SNP genotypes, but also sex and age.
We also investigated if there was any association between genotypes and biochemical characteristics of T2D. Therefore, we performed tests to determine the normality of the biochemical characteristics. Fasting plasma insulin and triglyceride variables were normalized by log transformation, and cholesterol was normalized by square root transformation, before ANOVA analysis. For the other characteristics (BMI, fasting glucose, c-peptide, HbA1C, LDL, HDL, and HOMA-IR), the Kruskal-Wallis test was performed. The SNP genotypes were coded as 11, 12 and 22. Then, a single point (single SNP) regression analysis model was fitted. Linkage disequilibrium (LD) analysis was performed with MIDAS software. 9 All analyses were carried out using SPSS 18.0 (IBM Corp., Armonk, USA). In all analyses, p-value ≤0.05 was considered statistically significant.
Results
Characteristics of study subjects
A total of 840 individuals, including 427 diabetic individuals (206 obese and 221 non-obese) and 413 nondiabetic individuals (138 obese and 275 non-obese), were enrolled in this study. The clinical and biochemical characteristics of the individuals studied are shown in Table 2 .
Association study
The genotype distribution and association analyses of SNPs are summarized in Table 3 . The silent SNP rs706713 in exon 1 of the PIK3R1 gene showed a significant association with T2D (OR 1.7 (95% confidence interval -CI: 1.09-2.40), p = 0.016 and OR 1.5 (95% CI: 1.054-2.233), p = 0.025, additive and dominant models, respectively) when individuals were considered as patient and control groups. When the obese and non-obese groups were evaluated separately, a strong relationship between SNP The SNP rs3730089 in exon 6 causes an amino acid substitution in the protein, and was significantly associated with T2D (OR 3.5 (95% CI: 1.015-11.762), p = 0.047, recessive model). The genotype distribution for this SNP was found to deviate from HWE in the control groups (p < 0.05).
While the intronic SNP rs7709243 was associated with T2D in the obese group (OR 2.5 (95% CI: 1.239-4.891), p = 0.01 and OR 2.4 (95% CI: 1.309-4.418), p = 0.005, additive and recessive models, respectively), the rs7713645 SNP was associated with the disease in both the obese group (OR 2 (95% CI: 1.081-3.773), p = 0.03 and OR 2 (95% CI: 1.101-3.514), p = 0.022, additive and recessive models, respectively) and the non-obese group (OR 2 (95% CI: 1.081-3.906), p = 0.03 and OR 1.9 (95% CI: 1.079-3.235), p = 0.03, additive and recessive models, respectively). With the exception of the genotype distribution of SNP rs7709243 in the non-obese diabetic group, both of the SNPs located in intron 1 were in HWE. Neither the SNP rs1550805 in intron 6 nor the SNP rs3756668 in the 3'UTR of the PIK3R1 gene were associated with T2D (p > 0.05) when the groups were assessed together or separately. The genotype distributions of both SNPs showed deviation from HWE in the control groups.
Additionally, linkage disequilibrium was calculated for the 6 SNPs and r 2 values were used to provide evidence of pairwise LD between the SNPs. Only the rs7709243 and rs7713645 SNPs located in intron 1 were found to be in strong LD (D' = 0.85; r 2 = 0.7). The LD between the other variants was weak.
Genotype-phenotype relationship
The effects of the SNPs on phenotypic characteristics such as fasting glucose, insulin, c-peptide, hemoglobin A1C levels, triglycerides, cholesterol, LDL and HDL levels, BMI, and HOMA-IR value as an insulin resistance marker were analyzed in this study. The SNP rs706713 in exon 1 had a strong effect on HOMA-IR (p = 0.018). The intronic SNP rs7709243 showed an effect on LDL level (p = 0.028) and cholesterol (p = 0.008), while the other intronic SNP, rs1550805, had a strong effect on c-peptide level (p = 0.023) and BMI (p = 0.007).
Discussion
Insulin has both metabolic and growth-stimulating effects, and its metabolic effect occurs through the PI3K/Akt pathway. 10 Although other growth factors also activate PI3K via distinct receptor tyrosine kinases, PI3K activation, which occurs only through insulin effect, has been found to regulate metabolic homeostasis. 11 In adipocyte cell cultures, it was revealed that both insulin and platelet-derived growth factor (PDGF) activate PI3K, and that insulin stimulates GLUT4 translocation to the plasma membrane, while PDGF does not. 12 Insulin resistance develops as a result of the reduced responsiveness of target tissues to insulin due to decreased receptor and/or downstream signaling protein activity, rather than a reduced circulating insulin level. 13, 14 PI3K/Akt plays a central role in several pathway-related energy homeostases, including leptin, pro-opiomelanocortin (POMC), TNF-a, adiponectin, and cytokine stimulation. [15] [16] [17] [18] PI3K consists of a catalytic subunit (p110) and a regulatory subunit (p85α). 5 The p85α subunit provides stability and maintains the activity of the p85α/p110 complex. 1, 5 In addition, the monomer p85α is in competition with the p85α/p110 complex for binding to IRS1 or allosteric interaction with p110, provide negative regulation of the p85α/p110 complex. 19 The overexpression of p85α by hormonal or experimental induction weakens signal transmission and causes insulin resistance by disrupting the activity of the p85α/p110 complex and the connection between PI3K and IRS1. 20, 21 This study found that the SNPs localized in the PIK3R1 gene, encoding p85α regulatory subunit of PI3K which plays a critical role in signal transduction, are associated with T2D, obesity and related phenotypic characteristics. Reports have indicated that SNPs rs706713 (Tyr73Tyr) and rs3730089 (Met326Ile) in exons 1 and 6, respectively, have reduced protein activity and are associated with T2D. 22, 23 Additionally, we also detected a significant association between rs706713 and T2D (p < 0.05). When the patients were divided into obese and non-obese groups, rs706713 was associated with the disease in the non-obese group (p = 0.05). The patient and control groups were in HWE for the SNP rs706713. We also found that this SNP had an effect on HOMA-IR (p = 0.018) and c-peptide (p = 0.007) levels, although no effect was found on obesity, glucose or insulin levels, a finding that is consistent with a report from Jamshidi et al. 23 This silent substitution might be interacting with other known and unknown variants.
Many studies have reported conflicting results regarding the association between the Met326Ile (rs3730089) variant in exon 6 of the PIK3R1 gene and insulin resistance and T2D. While this SNP was not found to be a risk factor for diabetes in a Danish population, it was associated with the disease in a Chinese population. 24, 25 This inconsistency in results may be due to differences in sample size and the studied populations. There is evidence that European and Asian populations have different allele frequencies, risk allele profiles, risk genes, and so on. 26 We also observed a strong association between Met326Ile and the disease (p < 0.05). This missense variation is located between the N-terminal-Src homology region (N-SH2) and the BH region which has homology with GTPase activating protein (GAP). The SH2 domains include tyrosine residues and mediate binding to phosphotyrosine residues in the YXXM motif in receptor and adaptor molecules. 27 Therefore, the Met326Ile variation may alter protein activity by affecting binding to its receptor and adaptor molecules. In our study, the genotype distributions of Met326Ile deviated from HWE in the control groups (p < 0.05). This deviation should be taken into account while assessing the results for Met326Ile. Future studies are needed to reanalyze the results after increasing the sample size to reach equilibrium.
Jamshidi et al. investigated intronic SNPs in the PIK3R1 gene, specifically rs7713645 and rs7709243 in intron 1 and rs1550805 in intron 6, showing that SNPs rs7713645 and rs7709243 were associated with BMI, fasting glucose level and glucose level during the 2 nd hour of oral glucose application and that rs1550805 was significantly associated with BMI, body weight and central adiposity. 23 These results indicate the existence of a strong link between these intronic SNPs, especially rs1550805, and obesity.
In our study, we observed strong associations between the SNPs rs7709243 and rs7713645, and T2Din obese patients (p < 0.05) and between the SNP rs7713645 and T2D in non-obese patients (p < 0.05). In addition, the rs7709243 variant was determined to have an effect on cholesterol (p = 0.008) and LDL (p = 0.028) levels.
On the other hand, we did not detect any association between the intronic SNP rs1550805 and T2D. However, this SNP had an effect on c-peptide (p = 0.023) and BMI (p = 0.007). These results support the hypothesis that the intronic SNPs in the PIK3R1 gene have significant effects on BMI and lipid parameters. Because this significant association with T2D was especially observed in the obese group, one could suggest that the rs7709243 and rs7713645 substitutions play a role in the development of T2D through the development of obesity. Additionally, the genotype distributions of these T2D-associated intronic SNPs were in HWE in all groups. Moreover, according to LD analysis, we detected significant linkage only between SNPs rs7709243 and rs7713645 (D' = 0.85; r 2 = 0.7). Localization at the same intron of both variants might explain this linkage.
Since 2007, more than 60 variants have been shown to be associated with T2D by genome wide association (GWA) analysis, which was performed in numerous populations with large samples. It is noteworthy that the vast majority of these variants are intronic variants. These SNPs do not cause any changes in protein structure but show a strong association with type 2 diabetes, suggesting that they are intronic enhancers. 28 Additionally, it has been proposed that these variants can be haplotyped with other functional variants. 29 It has been reported that the SNPs in the noncoding UTR sequence of the PIK3R1 gene, especially SNP rs3756668 in the 3'UTR region, are associated with a high risk of diabetes and elevated BMI as well as increased risk for insulin resistance. 30 Additionally, the same study revealed that this SNP also has an effect on fasting glucose and fasting insulin levels. 30 However, our study did not identify a relationship between SNP rs3756668 and T2D or its phenotypes in obese and non-obese individuals in the Turkish population. We suspect that the deviation from HWE in the control group may have influenced our results. Reassessing these results after increasing the population size to reach equilibrium will increase reliability.
Jamshidi et al. investigated the association between the tag SNPs including rs706713, rs7713645, rs7709243, rs251406, rs40318, rs1550805, rs831125 and rs3730089 of the PIK3R1 gene, and BMI, serum leptin level, and glucose/insulin homeostasis in a large population of female twins. 23 According to their report, rs1550805 in particular was determined to have a strong relationship with serum leptin level and BMI (p < 0.05). Consistently, in our study, only rs1550805 was associated with BMI, supporting the findings of Jamshidi et al. 23 Our study is the 1 st to show that SNPs rs706713 (Tyr73Tyr) and rs3730089 (Met326Ile), which are located in exons, and SNPs rs7713645, rs7709243 and rs1550805, which are located in introns, are significantly associated with T2D and have effects on phenotypic features such as obesity, insulin resistance and lipid parameters in a Turkish population. The only exception was SNP rs3756668, which is located in the 3'UTR. Our research findings support the idea that SNPs located in the PIK3R1 gene can affect insulin signaling transduction and thus may play a role in the development of T2D through the development of insulin resistance.
